Active Learning-Guided Seq2Seq Variational Autoencoder for Multi-target Inhibitor Generation
This addresses the problem of multi-target drug discovery for researchers, offering a generalizable computational framework, though it appears incremental as it builds on existing active learning and VAE methods.
The paper tackled the challenge of designing molecules that inhibit multiple therapeutic targets simultaneously by proposing an active learning-guided Seq2Seq variational autoencoder, which generated a diverse set of pan-inhibitor candidates for three coronavirus proteases in a proof-of-concept study.
Simultaneously optimizing molecules against multiple therapeutic targets remains a profound challenge in drug discovery, particularly due to sparse rewards and conflicting design constraints. We propose a structured active learning (AL) paradigm integrating a sequence-to-sequence (Seq2Seq) variational autoencoder (VAE) into iterative loops designed to balance chemical diversity, molecular quality, and multi-target affinity. Our method alternates between expanding chemically feasible regions of latent space and progressively constraining molecules based on increasingly stringent multi-target docking thresholds. In a proof-of-concept study targeting three related coronavirus main proteases (SARS-CoV-2, SARS-CoV, MERS-CoV), our approach efficiently generated a structurally diverse set of pan-inhibitor candidates. We demonstrate that careful timing and strategic placement of chemical filters within this active learning pipeline markedly enhance exploration of beneficial chemical space, transforming the sparse-reward, multi-objective drug design problem into an accessible computational task. Our framework thus provides a generalizable roadmap for efficiently navigating complex polypharmacological landscapes.